In a patient with severe dementia (MMSE score 11), what medication should be initiated?

Medication for Severe Dementia (SLUMS 11)

Start memantine 5 mg daily, titrating to 20 mg daily over 4 weeks, as this is the primary evidence-based medication for moderate-to-severe dementia. If the patient is not already on a cholinesterase inhibitor, consider adding donepezil 5-10 mg daily for additional cognitive and functional benefit 1.

Understanding the Clinical Context

A SLUMS score of 11 indicates severe cognitive impairment, roughly equivalent to an MMSE of 10-12. At this stage of dementia, the evidence base shifts dramatically from mild-to-moderate disease:

• Memantine becomes the primary agent with demonstrated efficacy in moderate-to-severe Alzheimer disease, showing significant improvements on the Severe Impairment Battery (SIB) and global function measures 1
• Cholinesterase inhibitors retain benefit even in severe disease, contrary to older practice patterns of discontinuation 2

Medication Algorithm for Severe Dementia

First-Line: Memantine

• Dosing: Start 5 mg daily, increase by 5 mg weekly to target 20 mg daily (or 10 mg twice daily)
• Evidence: Studies in moderate-to-severe Alzheimer disease showed statistically significant improvements in cognition (SIB), global function (CIBIC-plus), behavior (Neuropsychiatric Inventory), and activities of daily living 1
• Safety profile: Better tolerated than cholinesterase inhibitors with lower withdrawal rates due to adverse events 1

Consider Adding: Cholinesterase Inhibitor (Donepezil Preferred)

• Dosing: Donepezil 5 mg daily for 4-6 weeks, then increase to 10 mg daily
• Evidence: The landmark DOMINO-AD trial demonstrated that continuing donepezil in moderate-to-severe disease (SMMSE 5-13) resulted in cognitive benefits exceeding the minimum clinically important difference (1.9 points on SMMSE) and significant functional benefits over 12 months 2
• Combination therapy: Donepezil plus memantine showed a mean difference of 2.57 points on MMSE compared to placebo, though evidence for synergistic benefit over monotherapy is mixed 3, 2

Critical Clinical Considerations

Do NOT discontinue cholinesterase inhibitors just because dementia has progressed to severe stage. This is a common error. The DOMINO-AD trial specifically showed that patients who discontinued donepezil experienced significant cognitive and functional decline compared to those who continued treatment 2. This represents Grade A evidence against the outdated practice of stopping these medications in advanced disease.

Monitoring Parameters

• Cognition: Use Severe Impairment Battery (SIB) rather than MMSE at this stage, as MMSE has floor effects in severe dementia
• Function: Bristol Activities of Daily Living Scale or ADCS-ADL-severe version
• Behavioral symptoms: Neuropsychiatric Inventory
• Reassess at 3-6 months to determine if clinically meaningful benefit is occurring

Adverse Events to Monitor

• Memantine: Generally well-tolerated; watch for dizziness, confusion, agitation (8-32% incidence) 1
• Donepezil: Gastrointestinal effects (nausea, diarrhea, vomiting), bradycardia, syncope; dose-dependent adverse events with higher rates at 10 mg vs 5 mg 4

Dementia Subtype Considerations

If the patient has Lewy body dementia (DLB or Parkinson disease dementia):

• Prioritize cholinesterase inhibitors (donepezil or rivastigmine) as first-line, with stronger evidence than in Alzheimer disease 5, 6
• Memantine can be added but has less robust evidence in Lewy body dementias 5

If vascular dementia:

• Evidence is weaker overall, but memantine showed significant benefits on ADAS-cog in vascular dementia trials 1
• Cholinesterase inhibitors may help in mixed dementia (Alzheimer plus vascular) 5

What NOT to Do

• Do not use tacrine: Obsolete due to hepatotoxicity (4-67% elevated liver enzymes) and high withdrawal rates 1
• Do not use these for prevention or mild cognitive impairment: No evidence of efficacy 5
• Avoid stopping medications solely due to disease progression: This worsens outcomes 2

The evidence strongly supports active pharmacological treatment even at this severe stage, with memantine as the cornerstone and continuation (or initiation) of cholinesterase inhibitors providing additional benefit on cognition and function that exceeds clinically meaningful thresholds 1, 2.